FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Monday

 

Association between low testosterone and brain atrophy in men multiple sclerosis: STUDY




































Image source: LIMERICKCC.IE

Abstract

Objective:
To determine the association between testosterone levels and brain atrophy in men with multiple sclerosis (MS).

Background:
In men with MS, low testosterone levels are associated with greater disease severity. Given the neuroprotective effects of testosterone noted in animal models, we hypothesized that low testosterone would be associated with brain atrophy in relapsing remitting MS (RRMS).

Design/Methods:
Thirty-eight male patients, aged 18-65 years, with RRMS or clinically-isolated syndrome and first symptoms < 10 years prior were selected from a longitudinal clinical study. We measured testosterone in stored morning blood samples. We calculated brain parenchymal fraction (BPF), a surrogate of whole brain atrophy, using expert manual correction of an automated template driven segmentation.

Results:
The patients had a mean (SD) age of 40.3 (10.0) years, EDSS of 0.99 (0.94) and disease duration of 4.6 (2.2) years. Mean total testosterone levels were 375 ng/dL (SD= 153; range= 49-672 ng/dL); 31.6[percnt] men were hypogonadal (<288 ng/dL). Testosterone levels were not correlated with vitamin D, smoking status or MS treatment. There was no significant age-adjusted correlation between testosterone levels and BPF (partial Pearson’s correlation r=0.252; p=0.132). However, when we classified testosterone levels into clinically meaningful categories (<288, 289-600, and above 600 ng/dL), we detected a marginally significant association with BPF (p=0.052 for three group comparison). The estimated group difference between the highest and lowest testosterone levels was 0.042, with lower testosterone levels associated with worse atrophy ( p=0.050 for group comparison after Bonferroni correction). We will present analyses, including longitudinal, from a larger cohort, at the Conference. 

Conclusions:
This exploratory study suggests that low testosterone levels may be associated with brain atrophy in early MS. A potential neuroprotective role for testosterone warrants further investigation. STUDY SUPPORTED BY: NMSS, American Brain Foundation.


Story Source: The above story is based on materials provided by NEUROLOGY
Note: Materials may be edited for content and length

Labels: ,



Go to Newer News Go to Older News